Cardiol Therapeutics (CRDL) Stock Price, Quote & News

Company Profile

Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the developing of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutan...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 289 910 0850

Fax: 905 481 2394

Website: www.cardiolrx.com

Address:

2265 Upper Middle Road East, Suite 602, Oakville, Canada

RobbyAxelrod1 Jan. 7 at 3:30 PM

$CRDL Hugging that 1$ very nice.

0 · Reply

BigWig8560 Jan. 7 at 2:48 PM

$CRDL

0 · Reply

Covode13 Jan. 6 at 11:55 PM

$CRDL more of a lot of nothing here. All these results going no where

1 · Reply

Youth_It Jan. 6 at 10:06 AM

$CRDL Facts don’t need applause to stay true. Everybody who follows your $CRDL Advertisments knows what you and your various Alias are. A paid AI - pumper !!

1 · Reply

Fastcapital Jan. 6 at 9:58 AM

$CRDL @Youth_It When someone can’t engage with the data, they default to conspiracy and sarcasm. Calling detailed discussions about trials, MRI endpoints, enrollment timelines and regulatory paths “paid stories” isn’t insight it’s avoidance. These aren’t opinions from 2024, they’re facts on the table today. If that’s entertaining to you, fine but it doesn’t change the science or the progress. Facts don’t need applause to stay true.

0 · Reply

Youth_It Jan. 6 at 9:57 AM

$CRDL FAST Lost CAPITAL is back. Thank you very much for that. Now we get his paid OLD stories ( since 2024) and his 🤔outstanding 🤣expertise again. Paid for by whoever. 🤔You are worth your money as an entertainer.

0 · Reply

Covode13 Jan. 5 at 6:01 PM

$CRDL just wait till 2027 to buy. We aren’t moving above 1.10 for awhile

1 · Reply

Fastcapital Jan. 5 at 5:22 PM

$CRDL 2026 is shaping up as a catalyst-heavy year for Cardiol, and the setup is being underestimated. Key upcoming milestones to watch: • MAVERIC Phase 3: 50% enrollment expected around this period, with full enrollment guided for H1 2026. Execution milestone that materially lowers risk. • Orphan Drug Designation (myocarditis): ARCHER Phase 2 data strengthens the medical rationale; filing and potential designation expected in 2026. • Patent issuance: Following the November allowance, the patent is expected to be formally issued in Q1 2026, strengthening IP and partner value. • Regulatory interactions: Ongoing FDA engagement around ARCHER and MAVERIC. • Partnership discussions: Management has confirmed active talks with large pharma; updates may align with milestones. • Strong balance sheet: Cash runway into late 2027 removes financing overhang. Markets don’t price milestones before they arrive they reprice after. 2026 looks like the year execution turns into recognition.

3 · Reply

revuelto Jan. 5 at 3:08 AM

$CRDL looks interesting at first glance but I need to dig in a bit more before starting a position ✌️

1 · Reply

Market_Luther_Kang Jan. 3 at 6:46 PM

$CRDL I’ve been mapping out the exit strategy for Cardiol, and the stars are aligning for a massive Early 2027 acquisition. Here is why the Smart Money is waiting for that specific window: 1️⃣ The MAvERIC P3 Topline: We’re looking at Phase 3 results for Recurrent Pericarditis hitting the tape around late '26/early '27. Once that data is official, the Orphan Drug de-risking is 100% complete. Big Pharma (Sanofi/Amgen) won't wait for the FDA ink to dry; they’ll buy the revenue stream early. 2️⃣ The CRD-38 Bioavailability Proof: By early 2027, we’ll have the full readout from the CRD-38 Phase 1. If that SubQ shot confirms 80%+ bioavailability, it transforms Cardiol from a rare disease micro-cap into a Heart Failure Blockbuster powerhouse. Big Pharma likes to buy when the Safety (P3 MAvERIC) and the Upside (P1 CRD-38) are both proven. Early 2027 is the sweet spot where the valuation gap finally closes. We aren't just holding for a 20% pop; we are holding for the $2B+ buyout.

0 · Reply

New Data from the Phase II ARCHER Trial Demonstrate CardiolRx(TM) Improves Heart Structure in Patients with Acute Myocarditis, Supporting Expansion Across Inflammatory Cardiac Conditions

Nov 13, 2025, 7:45 AM EST - 7 weeks ago

Cardiol Therapeutics Receives U.S. Patent Allowance Broadly Protecting its Heart Drugs to Late 2040

Nov 5, 2025, 7:45 AM EST - 2 months ago

Cardiol Therapeutics' Phase II ARCHER Trial Results to be Presented at the European Society of Cardiology Scientific Meeting on Myocardial & Pericardial Diseases

Oct 21, 2025, 7:27 AM EDT - 2 months ago

Cardiol Therapeutics Completes US$11.4 Million Financing and Extends Cash Runway into Q3 2027

Oct 17, 2025, 4:34 PM EDT - 2 months ago

Cardiol Therapeutics Secures US$11 Million Financing and Extends Cash Runway into Q3 2027

Aug 11, 2025, 7:27 AM EDT - 5 months ago

Cardiol Therapeutics to Participate in Fireside Chat at Canaccord Genuity's 45th Annual Growth Conference

Aug 6, 2025, 7:27 AM EDT - 5 months ago

Cardiol Therapeutics Announces Topline Results from the Phase II ARCHER Trial of CardiolRx(TM) in Acute Myocarditis

Jul 22, 2025, 7:27 AM EDT - 6 months ago

Cardiol Therapeutics Announces Database Lock for Phase II ARCHER Trial of CardiolRx(TM) in Acute Myocarditis

May 29, 2025, 7:27 AM EDT - 7 months ago

Cardiol Therapeutics Reports Results of 2025 Annual General Meeting of Shareholders

May 27, 2025, 7:27 AM EDT - 8 months ago

Cardiol Therapeutics to Webcast Virtual Annual General Meeting of Shareholders on May 28th at 4:30 p.m. EDT

Apr 29, 2025, 7:27 AM EDT - 9 months ago

Cardiol Therapeutics Nominates Dr. Timothy Garnett to Its Board of Directors

Apr 16, 2025, 7:27 AM EDT - 9 months ago

Cardiol Therapeutics Enrolls First Patient in Pivotal Phase III MAVERIC Trial in Recurrent Pericarditis

Apr 1, 2025, 7:27 AM EDT - 10 months ago

Cardiol Therapeutics Announces Year-End 2024 Update on Operations

Mar 3, 2025, 7:27 AM EST - 11 months ago

Cardiol Therapeutics to Present at TD Cowen 45th Annual Health Care Conference

Feb 20, 2025, 7:27 AM EST - 11 months ago

Cardiol Therapeutics Announces Publication of Research in the Journal of the American College of Cardiology: Basic to Translational Science That Supports Development of Its Proprietary Subcutaneous Drug Candidate, CRD-38, for the Treatment of Heart Failure

Feb 19, 2025, 12:13 AM EST - 11 months ago

Cardiol Therapeutics: Bargain Stock Price With Share Price Appreciation Catalysts

Feb 4, 2025, 7:27 AM EST - 1 year ago

Cardiol Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference

Dec 19, 2024, 8:30 AM EST - 1 year ago

PRISM MarketView Features Q&A with President and CEO David Elsley: Cardiol Therapeutics Enters Phase 3 Clinical Trial for CardiolRx™ Addressing Patients with Recurrent Pericarditis

Nov 18, 2024, 11:37 AM EST - 1 year ago

Cardiol Therapeutics' Phase II MAvERIC-Pilot Clinical Results in Recurrent Pericarditis Presented at the American Heart Association Scientific Sessions 2024

Nov 13, 2024, 8:00 AM EST - 1 year ago

Cardiol Therapeutics Inc. Added to PRISM Emerging Biotech Index

Oct 22, 2024, 6:30 AM EDT - 1 year ago

Cardiol Therapeutics to Advance CardiolRx(TM) into a Late-Stage Trial in Patients with Recurrent Pericarditis

Oct 11, 2024, 8:39 AM EDT - 1 year ago

Cardiol Therapeutics Announces Exercise and Closing of Over-Allotment Option

Oct 10, 2024, 9:09 AM EDT - 1 year ago

Cardiol Therapeutics Announces Closing of US$13.5 Million Public Offering of Common Shares

Oct 9, 2024, 7:58 AM EDT - 1 year ago

Cardiol Therapeutics Announces Pricing of Public Offering of Common Shares

Oct 8, 2024, 4:01 PM EDT - 1 year ago

Cardiol Therapeutics Files Preliminary Prospectus Supplement for Proposed Public Offering of Common Shares

Sep 24, 2024, 7:27 AM EDT - 1 year ago

Cardiol Therapeutics Achieves Target Patient Enrollment in its Phase II ARCHER Trial Investigating CardiolRx(TM) for Acute Myocarditis

Sep 10, 2024, 7:27 AM EDT - 1 year ago

Cardiol Therapeutics Announces Completion of the MAvERIC Phase II Study in Recurrent Pericarditis with Results to be Presented at the American Heart Association Scientific Sessions 2024

Jun 27, 2024, 12:29 PM EDT - 1 year ago

Cardiol Therapeutics Reports Results of 2024 Annual General and Special Meeting of Shareholders

Jun 25, 2024, 7:27 AM EDT - 1 year ago

Cardiol Therapeutics to Webcast Virtual Annual General and Special Meeting of Shareholders on June 26th at 4:30 p.m. EDT

Jun 13, 2024, 7:58 AM EDT - 1 year ago

Cardiol Therapeutics Announces Positive Topline Data from its Phase II MAvERIC-Pilot Study Investigating CardiolRx(TM) for Recurrent Pericarditis

May 14, 2024, 7:27 AM EDT - 1 year ago

Cardiol Therapeutics Announces Phase II ARCHER Trial Presented at the World Congress on Acute Heart Failure 2024

Apr 2, 2024, 6:00 AM EDT - 1 year ago

Cardiol Therapeutics Announces Year-End 2023 Update on Operations

Feb 21, 2024, 7:27 AM EST - 2 years ago

Cardiol Therapeutics Completes Patient Enrollment in its Phase II MAvERIC-Pilot Study Investigating CardiolRx(TM) for Recurrent Pericarditis

Feb 15, 2024, 7:27 AM EST - 2 years ago

Cardiol Therapeutics Granted Orphan Drug Designation for its Lead Drug Candidate for the Treatment of Pericarditis

Jan 24, 2024, 7:27 AM EST - 2 years ago

Cardiol Therapeutics Regains Compliance with all Applicable Listing Standards of The Nasdaq Capital Market

Jan 9, 2024, 7:27 AM EST - 2 years ago

Cardiol Therapeutics Announces it has Exceeded 50% Enrollment in its Phase II ARCHER Trial in Acute Myocarditis

Dec 5, 2023, 7:27 AM EST - 2 years ago

Cardiol Therapeutics Announces Massachusetts General Hospital, Largest Teaching Hospital of Harvard Medical School, as the 8th Major Medical Centre Participating in MAvERIC-Pilot

Nov 16, 2023, 5:30 AM EST - 2 years ago

Cardiol Therapeutics Announces Study Results Presented at the 2023 Annual Meeting of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases

Nov 1, 2023, 7:27 AM EDT - 2 years ago

Cardiol Therapeutics Announces It Has Exceeded 50% Enrollment in Its Phase II MAvERIC-Pilot Study in Recurrent Pericarditis

Oct 20, 2023, 5:00 PM EDT - 2 years ago

Cardiol Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement

Oct 10, 2023, 6:00 AM EDT - 2 years ago

Cardiol Therapeutics Announces Positive Study Results Demonstrating Cardioprotective Effects of Subcutaneously Administered Cannabidiol in a Model of Heart Failure with Preserved Ejection Fraction

Sep 26, 2023, 7:27 AM EDT - 2 years ago

Cardiol Therapeutics to Present at Cantor Fitzgerald 2023 Global Healthcare Conference

Sep 19, 2023, 7:27 AM EDT - 2 years ago

Cardiol Therapeutics Announces All Collaborating Clinical Research Centers Now Initiated and Eligible to Enroll Patients in ARCHER, a Phase II Trial of CardiolRx(TM) for the Treatment of Acute Myocarditis

Aug 9, 2023, 7:27 AM EDT - 2 years ago

Cardiol Therapeutics to Present at Canaccord Genuity 43rd Annual Growth Conference

Jun 29, 2023, 10:19 AM EDT - 2 years ago

Cardiol Therapeutics Reports Results of 2023 Annual General Meeting

Jun 27, 2023, 7:27 AM EDT - 2 years ago

Cardiol Therapeutics to Webcast Virtual Annual General Meeting on June 28th at 4:30 p.m. EDT

Mar 29, 2023, 7:27 AM EDT - 3 years ago

Cardiol Therapeutics Announces Year-End 2022 Update on Operations

Mar 7, 2023, 7:27 AM EST - 3 years ago

Cardiol Therapeutics Announces Study Results from Collaborating Research Center Demonstrating Cardioprotective Effects of Cannabidiol in a Model of Heart Failure

Jan 17, 2023, 7:27 AM EST - 3 years ago

Cardiol Therapeutics Announces First Patient Enrolled in Phase II Study Evaluating CardiolRx(TM) for the Treatment of Recurrent Pericarditis

Dec 12, 2022, 7:27 AM EST - 3 years ago

Cardiol Therapeutics Commences Multi-Center Phase II Pilot Study of CardiolRx(TM) for the Treatment of Recurrent Pericarditis

RobbyAxelrod1 Jan. 7 at 3:30 PM

$CRDL Hugging that 1$ very nice.

0 · Reply

BigWig8560 Jan. 7 at 2:48 PM

$CRDL

0 · Reply

Covode13 Jan. 6 at 11:55 PM

$CRDL more of a lot of nothing here. All these results going no where

1 · Reply

Youth_It Jan. 6 at 10:06 AM

$CRDL Facts don’t need applause to stay true. Everybody who follows your $CRDL Advertisments knows what you and your various Alias are. A paid AI - pumper !!

1 · Reply

Fastcapital Jan. 6 at 9:58 AM

0 · Reply

Youth_It Jan. 6 at 9:57 AM

0 · Reply

Covode13 Jan. 5 at 6:01 PM

$CRDL just wait till 2027 to buy. We aren’t moving above 1.10 for awhile

1 · Reply

Fastcapital Jan. 5 at 5:22 PM

3 · Reply

revuelto Jan. 5 at 3:08 AM

$CRDL looks interesting at first glance but I need to dig in a bit more before starting a position ✌️

1 · Reply

Market_Luther_Kang Jan. 3 at 6:46 PM

0 · Reply

Market_Luther_Kang Jan. 2 at 7:53 PM

$CRDL - The massive value gap the market is missing. 🫀 While everyone’s chasing the next AI play, I’m focused on a drug that’s actually rebuilding hearts. Here’s why $CRDL is my top conviction "Wealth Builder" for 2026: 1. Structural Repair > Symptom Management: Big Pharma is full of drugs that manage fluid. $CRDL is different. 9.2-gram reduction in heart mass in the ARCHER trial. That’s not just a "hit"—it’s Reverse Remodeling. 🛠️ 2. The Oral Advantage: Kiniksa ($KNSA) is a $2B company with a needle-based biologic. Cardiol has a once-daily pill. Doctors and patients choose pills over needles every single time. $CRDL is the "Arcalyst-Killer" at 1/10th the valuation. 💊

2 · Reply

Covode13 Jan. 1 at 8:41 PM

$CRDL

2 · Reply

Theo77 Dec. 31 at 10:05 PM

$CRDL Exchange rate CA$ 115.26 = US $ 83.98 🌟⭐️🤩👍😊

0 · Reply

Theo77 Dec. 31 at 10:03 PM

$CRDL

0 · Reply

Theo77 Dec. 31 at 7:52 PM

$CRDL Significantly undervalue 🤩

0 · Reply

mmtiddy Dec. 31 at 7:38 PM

$CRDL Why does this stock have such a republican fanbase

1 · Reply

mmtiddy Dec. 31 at 7:37 PM

$CRDL The same question was asked last year too, and it was a turd.

1 · Reply

PDM21 Dec. 31 at 7:22 PM

$CRDL tax harvest or turd? Answer is incoming soon.

1 · Reply

Covode13 Dec. 31 at 5:30 PM

$CRDL 2026 💩

0 · Reply

Fastcapital Dec. 31 at 3:25 PM

$CRDL As we head into 2026, this is shaping up to be Cardiol’s most important year yet. The company enters with a rare small-cap profile: an active Phase 3 program (MAVERIC) in an orphan cardiovascular indication, plus strong Phase 2 ARCHER data showing true disease modification with hard MRI endpoints — not just biomarkers. ARCHER demonstrated normalization of LV mass, ECV, and ICV within 12 weeks, providing mechanistic proof of structural heart recovery. That same mechanism directly strengthens the MAVERIC Phase 3 pericarditis program, reducing biological and regulatory risk. With cash runway into late 2027, ongoing partner discussions, and clear catalysts ahead, execution is now key. Wishing everyone a healthy and successful 2026.

0 · Reply

Theo77 Dec. 31 at 2:32 PM

$CRDL Happy New Year 2026 ! ⭐️🌟🚀🚀

0 · Reply

Nick_Ams Dec. 31 at 1:38 PM

$CRDL My fellow bulls, Since I’m a few hours ahead of most of you, I’m sending my best wishes for 2026 early. Take care, stay safe, and let’s make 2026 a banner year! 💥 💫 🤑 👊

0 · Reply

Market Cap	98.91M
Revenue (ttm)	0.00
Net Income (ttm)	-26.77M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	176,675
Avg Vol	491,642
Day's Range	N/A - N/A
Shares Out	99.49M
Stochastic %K	67%
Beta	1.04
Analysts	Strong Sell
Price Target	$6.74